AbolerIS Pharma has dosed the Phase I study’s first cohort subjects with ABO21009, aimed at treating rheumatoid arthritis (RA ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

Boehringer Ingelheim has begun the JADE Phase II trial to evaluate BI 1584862 as a first-in-class oral treatment for ...

Janux Therapeutics has commenced Phase Ib expansion trials with JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial.

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.

Chengdu Origen and Vanotech have initiated the first subject dosing in the Phase I trial, VAN-2401, of KH658 for treating wet ...

OBI Pharma has received clearance from the US FDA for an IND application for OBI-902 to begin a Phase I/II trial for advanced ...

AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...